Page last updated: 2024-08-26

bosentan anhydrous and Diabetic Angiopathies

bosentan anhydrous has been researched along with Diabetic Angiopathies in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ergul, A; Li, W; Sachidanandam, K1
Böhm, F; Brismar, K; Gonon, A; Pernow, J; Rafnsson, A; Settergren, M1
Allen, TJ; Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Kelly, DJ; Rumble, JR; van Eeden, P1
Fedak, PW; Ko, L; Li, RK; Li, SH; Maitland, A; Mickle, DA; Pomroy, NC; Rao, V; Verma, S; Weisel, RD1

Trials

1 trial(s) available for bosentan anhydrous and Diabetic Angiopathies

ArticleYear
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.
    Diabetologia, 2012, Volume: 55, Issue:3

    Topics: Aged; Albuminuria; Antihypertensive Agents; Bosentan; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelium, Vascular; Female; Humans; Hyperemia; Male; Microvessels; Middle Aged; Peripheral Vascular Diseases; Severity of Illness Index; Sulfonamides; Vasodilation

2012

Other Studies

3 other study(ies) available for bosentan anhydrous and Diabetic Angiopathies

ArticleYear
Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
    Neurological research, 2011, Volume: 33, Issue:2

    Topics: Animals; Atrasentan; Bosentan; Cerebral Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Male; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents

2011
Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes.
    Circulation research, 2000, Feb-04, Volume: 86, Issue:2

    Topics: Animals; Antihypertensive Agents; Blotting, Northern; Bosentan; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin Receptor Antagonists; Endothelium, Vascular; Epidermal Growth Factor; Extracellular Matrix; Gene Expression; Hypertrophy; In Situ Hybridization; Male; Mast Cells; Mesenteric Arteries; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides

2000
Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism.
    The Journal of thoracic and cardiovascular surgery, 2002, Volume: 123, Issue:6

    Topics: Antihypertensive Agents; Bosentan; Cells, Cultured; Diabetic Angiopathies; Endothelin Receptor Antagonists; Endothelin-1; Humans; Myocardial Reperfusion Injury; Peptides, Cyclic; Sulfonamides

2002